- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
Advances in genomic technologies in recent years have led to an increasing role for clinical genomics in nephrology practice. While this advance brings the promise of positive outcomes such as clearer diagnoses and robust information to guide clinical management, it also opens a range of logistical, technical, and ethical points for the nephrologist to consider.
Join us for part 2 of this informative international webinar where Professor Andrew Mallett, nephrologist and clinical researcher (Australia), and Dr Hila Rasouly, research scientist and genetic counselor (USA), discuss clinical genomics and its applications in kidney disease, including genetic testing for diagnosis and prognosis and the question of determining which patients to test, barriers to access, global differences across healthcare landscapes, and implications for the patient.
Part 1 of this webinar can be watched here:
*Professor Andrew Mallett and Dr Hila Milo Rasouly are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Sundar is an employee of OPDC.
James Cook University,
Professor Mallett leads the first and largest renal genetics clinical service and program in Australia. Having been a Churchill Fellow and an RACP Foundation Jacquot Research Establishment Fellow, he has a strongly emerging profile in the clinical care and research of inherited kidney disease and nephrogenetics nationally, regionally and internationally. The clinical and translational research he is undertaking includes the epidemiology of inherited kidney diseases, subspecialist models of clinical care for these diseases, and new and novel genetic sequencing for nephrogenetic diagnosis and discovery including approaches to functional validation.
Currently, a Professor in the College of Medicine (James Cook University), a Clinical Fellow (Institute for Molecular Bioscience, The University of Queensland), and a Co-Lead for the Renal Genetics Program (Genetic Health Queensland), Professor Mallett is also National Director of the KidGen Collaborative, Lead for two Rare Disease Flagships (Australian Genomics Health Alliance), Director of Clinical Research and Nephrologist (Townsville University Hospital), and previously visiting fellow at the Cambridge Institute for Medical Research and Addenbrooke’s Hospital, The University of Cambridge. He is committed to improving the understanding of inherited kidney disease as well as the clinical care and outcomes of Australians affected by it.
Associate Director of Education at the Center for Precision Medicine and Genomics, at Columbia University Medical Center*
Dr Rasouly is a Research Scientist and the Associate Director of Education at the Center for Precision Medicine and Genomics, at Columbia University Medical Center. Dr Rasouly earned her MS in genetic counseling from The Hebrew University and worked several years as a genetic counselor before earning her PhD in genetics and genomics from Boston University. Dr Rasouly went on to hold a postdoctoral scientist position at Columbia University before becoming faculty. She has several peer-reviewed scientific publications on genetic testing in kidney disease.
Dr Rasouly’s career goal is to combine genomic research and genetic counseling in order to better understand the molecular mechanisms of renal disorders, and translate that knowledge into the clinic in order to improve the management and care for those affected by kidney disease.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Shirin Sundar, PhD is a Senior Medical Science Liaison at Otsuka, based out of the San Francisco bay area. Dr Sundar earned her Master’s and PhD in Cell and Molecular Biology from Birla Institute of Technology and Science, Pilani, India and the Uniformed Services University, Bethesda, Maryland. She did her post-doctoral training at the Kidney Institute, University of Kansas on elucidating the molecular mechanisms of polycystic kidney disease (PKD), and preclinical drug development for PKD. Prior to joining Otsuka, Dr Sundar held an Assoc. Specialist Scientist position at the University of California San Francisco.
Dr Sundar has presented several abstracts and published peer-reviewed manuscripts in the areas of cellular oxidative stress, innate immune pathways, polycystic kidney disease, and hyponatremia outcomes research.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
January 31 from 12:00 pm to 1:00 pm
February 14 from 12:00 pm to 1:00 pm
- Resource Center
- Patient Resources